NanoDimension Inc. Sells 56,222 Shares of Icosavax, Inc. (NASDAQ:ICVX)
NanoDimension Inc. Sells 56,222 Shares of Icosavax, Inc. (NASDAQ:ICVX)
NanoDimension Inc. lowered its position in Icosavax, Inc. (NASDAQ:ICVX – Get Rating) by 2.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,693,772 shares of the company's stock after selling 56,222 shares during the period. Icosavax accounts for 41.6% of NanoDimension Inc.'s portfolio, making the stock its largest holding. NanoDimension Inc. owned 0.07% of Icosavax worth $18,964,000 at the end of the most recent quarter.
根据向美国证券交易委员会提交的最新13F表文件,NanoDimension Inc.在第一季度将其在Icosavax, Inc.(纳斯达克股票代码:ICVX — 获取评级)的头寸下调了2.0%。该基金在此期间出售了56,222股股票后,拥有该公司2,693,772股股票。Icosavax 占 NanoDimension Inc. 41.6% 的股份。”的投资组合,使该股成为其最大的持股量。在最近一个季度末,NanoDimension Inc.拥有Icosavax0.07%的股份,价值18,964,000美元。
A number of other hedge funds have also recently added to or reduced their stakes in ICVX. Allspring Global Investments Holdings LLC bought a new stake in Icosavax during the fourth quarter worth approximately $138,000. New York State Common Retirement Fund boosted its position in Icosavax by 36.7% during the fourth quarter. New York State Common Retirement Fund now owns 8,340 shares of the company's stock worth $191,000 after purchasing an additional 2,240 shares during the period. ProShare Advisors LLC bought a new stake in Icosavax during the fourth quarter worth approximately $201,000. JPMorgan Chase & Co. boosted its position in Icosavax by 67.6% during the first quarter. JPMorgan Chase & Co. now owns 19,548 shares of the company's stock worth $138,000 after purchasing an additional 7,883 shares during the period. Finally, Swiss National Bank bought a new stake in Icosavax during the fourth quarter worth approximately $597,000. Institutional investors and hedge funds own 79.43% of the company's stock.
其他一些对冲基金最近也增加了或减少了在ICVX的股份。Allspring Global Investments Holdings LLC在第四季度购买了价值约13.8万美元的新股份。纽约州共同退休基金在第四季度将其在Icosavax的头寸增加了36.7%。纽约州共同退休基金在此期间又购买了2,240股股票后,现在拥有该公司8,340股股票,价值19.1万美元。ProShare Advisors LLC在第四季度收购了Icosavax的新股份,价值约20.1万美元。摩根大通在第一季度将其在Icosavax的头寸提高了67.6%。摩根大通在此期间又购买了7,883股股票后,现在拥有该公司19,548股股票,价值13.8万美元。最后,瑞士国家银行在第四季度购买了Icosavax的新股份,价值约59.7万美元。机构投资者和对冲基金拥有该公司79.43%的股票。
Analyst Ratings Changes
分析师评级变化
Separately, Evercore ISI raised Icosavax from an "in-line" rating to an "outperform" rating and set a $18.00 target price for the company in a research report on Wednesday, June 29th.
另外,Evercore ISI在6月29日星期三的一份研究报告中将Icosavax的评级从 “同步” 上调至 “跑赢大盘”,并为该公司设定了18.00美元的目标价格。
Insider Activity
内幕活动
Icosavax Stock Performance
Icosavax 股票表现
Shares of ICVX traded up $0.41 during mid-day trading on Wednesday, hitting $6.06. The company's stock had a trading volume of 2,154 shares, compared to its average volume of 113,413. Icosavax, Inc. has a one year low of $4.00 and a one year high of $41.98. The firm has a market capitalization of $241.67 million and a PE ratio of -2.11. The stock's 50-day moving average is $7.67 and its two-hundred day moving average is $9.81.
ICVX的股价在周三午盘交易中上涨了0.41美元,达到6.06美元。该公司的股票交易量为2,154股,而平均交易量为113,413股。Icosavax, Inc. 创下4.00美元的一年低点和41.98美元的一年高点。该公司的市值为2.4167亿美元,市盈率为-2.11。该股的50天移动平均线为7.67美元,其两百天移动平均线为9.81美元。
About Icosavax
关于 Icosavax
(Get Rating)
(获取评分)
Icosavax, Inc, a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial.
生物制药公司Icosavax, Inc正在开发针对传染病的疫苗。该公司借助其类病毒粒子(VLP)平台技术,主要专注于危及生命的呼吸系统疾病。其在研产品包括具有呼吸道合胞病毒靶点的候选疫苗 IVX-121,正在进行1/1b期临床试验;IVX-A12,具有呼吸道合胞病毒/人类偏肺病毒(hmPV)双价靶向适应症的呼吸道合胞病毒(RSV)单价抗原候选药物;IVX-241,具有SARS-CoV-2靶标的原始受体结合域(RBD)序列抗原正在进行1/2期临床试验。IVX-411
Featured Stories
精选故事
- Get a free copy of the StockNews.com research report on Icosavax (ICVX)
- NYSE Stocks Give Investors a Variety of Quality Options
- Zoom Video Communications Valuation Is Realigned With Reality
- The J.M. Smucker Company Proves Why Staples Are Outperforming
- Will the Real Palantir Please Stand Up?
- Foot Locker Just Because A Very Tempting Buy
- 免费获取 StockNews.com 关于 Icosavax (ICVX) 的研究报告的副本
- 纽约证券交易所股票为投资者提供多种优质选择
- Zoom 视频通信估值已与现实保持一致
- J.M. Smucker 公司证明了斯台普斯表现跑赢大盘的原因
- 真正的帕兰蒂尔会站起来吗?
- Foot Locker 只是因为买的很诱人
Want to see what other hedge funds are holding ICVX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Icosavax, Inc. (NASDAQ:ICVX – Get Rating).
想看看还有哪些对冲基金持有ICVX吗? 访问Holdingschannel.com,获取Icosavax, Inc.(纳斯达克股票代码:ICVX — 获取评级)的最新13F文件和内幕交易。
Receive News & Ratings for Icosavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icosavax and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Icosavax Daily 的新闻和评级 -在下面输入您的电子邮件地址,通过Marketbeat.com的免费每日电子邮件时事通讯接收Icosavax及相关公司的最新新闻和分析师评级的简明每日摘要。